

REMARKS

Claims 1-21, 22-24 and 27-30 are currently pending.

The Examiner previously required restriction and Applicants duly elected the Examiner's designated Group II, claims 22-23 and claims 27-30 directed to ectoparasitocidal compositions. The elected species was pyrimidines of formula I as indicated by the Examiner on page 3 of the current Office Action.

While Applicants still offer that it would not be unduly burdensome on the part of the Examiner to examine all species; however, for the sake of progressing prosecution on this case, Applicants elected the species designated herein.

Applicants are now requested to duly elect a single disclosed species. Applicants elect the species 4, 6-bis-(4-fluoro-3-(trifluoromethyl)phenoxy)-pyrimidin-5-ylamine, as shown in Example 3, page 29 of Applicants specification, and in Table 1, Compound No. 1.9 of page 31 of Applicants' specification. Each of the claims, 22-23 and 27-30 is directed to the elected species, wherein R₁, R₂, R₃, R₄, R₅, R₇, R₈, R₉, R₁₀, R₁₂ and R₁₃ are each H; R₆ is fluorine, R₁₁ is fluorine, X₁ is O; and X₂ is O. Upon allowance of a generic claim, Applicants respectfully request consideration of additional species.

Applicant authorizes the Commissioner to charge all fees due to Deposit Account 50-4389. Applicants believe this case is now in condition for review and Allowance. The Examiner is requested to contact the below signed attorney should any questions arise.

Respectfully submitted,

Date: Aug 29, 2008


By: 

Kimberly H. Parker
Attorney for Applicants
Reg. No. 47,843

Novartis Animal Health US, Inc.
3600 Northline Avenue, Suite 300
Greensboro, NC 27408
(336) 387-1443

Certificate of Transmission

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent & Trademark Office at (571) 273-8300 on August 29, 2008.


Kimberly H. Parker